• Home
  • Search Results

Research Studies

UNC-Chapel Hill Division of Hematology

35 studies match your search
By physician referral or invitation only

Testing the Usability of a Patient-Centered Tool

We are developing a computer-based tool for people who have cancers of the blood, bone marrow, and lymph nodes. This tool will help us understand what is most important to patients when it comes to the results of their treatment. We are looking for healthy volunteers (those without cancer) to help us test the usability of this tool.

Age & Gender
  • 21 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

This phase I trial is to find out the best dose, possible benefits and/or side effects of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Not currently enrolling

Multicenter study to learn more about brain avms and bleeding in people with Hereditary Hemorrhagic Telangiectasia (HHT)

The purpose of this study is to learn more about brain AVMs (BAVMs) and bleeding in HHT. We plan to study risk factors for rupture of BAVMs and also for other bleeding and features of HHT disease, including primarily genetics and imaging characteristics of the BAVMs. We hope that knowledge about risk factors will help improve the care and management of HHT patients.

Age & Gender
  • 0 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
Open

PD-1 blocker and gene therapy study for patients with Hodgkin Lymphoma

Do you have Hodgkin's Lymphoma that has either come back or did not get better after CAR-T therapy? If so, you may be able to take part in a study that will use anti-PD-1 therapy to treat your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Registry for Adults With Plasma Cell Disorders.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
By physician referral or invitation only

AMC-114 - Paclitaxel or Liposomal Doxorubicin for HIV-positive Persons with Kaposi Sarcoma

This study is being done to answer the following question: Do two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating KS in PLWH in sub-Saharan Africa? We are doing this study because we want to find out if one of these approaches, PTX or PLD, is better than the other for KS. Both drugs may be given as part of the usual approach for your KS. The usual approach is defined as care most people get for KS.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Sarcoma (bone and soft tissue))
  • HIV/AIDS
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

AUNT Study

To study individuals with sickle cell trait (SCT) and examine if their levels of hemoglobin S have any influence on red blood cells, clotting or kidney function.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

GBT021601-021

To evaluate the safety, tolerability, and efficacy of GBT021601 in adult participants with SCD to determine an optimal dose.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Leukemia

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A

Purpose: Evaluate the efficacy of prophylactic Emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research